SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 4 — Focused Visit (Follow-up) — Wilma Rudolph

PatientWilma Rudolph
Date of birth1972-06-23
IdentifiersMRN HR-ML036-SYN; SSN (made up) 000-36-5170
Document date2026-09-14
AuthorGloria Haynes-Whitaker, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Review at the end of six weeks of radiotherapy with daily temozolomide. [S]

History of Present Illness

Ms. Rudolph returns on the first weekday after her last radiotherapy fraction. She completed all 30 fractions and took temozolomide every day without a break, the 42nd and last dose last night. Nausea was mild and controlled by ondansetron before each dose. She stopped dexamethasone a month ago and her fingerstick glucose readings came back below 120 mg/dL, so she stopped checking. She is more tired each week, sleeps after lunch and has worked only a few hours a day for the past two weeks. Her hair has fallen out over the treated area and the skin there is pink. She has had no headache, seizure, change in speech, weakness, fever, bruising, cough or fall. The weekly blood counts at the radiation clinic were normal in the first five weeks; the week 6 count was not drawn. She has read about tumor-treating fields and wants to talk about them. She has had no thoughts of self-harm. [S]

ElementDetail
TreatmentRadiotherapy 60 Gy in 30 fractions and 42 days of temozolomide completed on schedule
SteroidOff dexamethasone for a month; glucose normal
SymptomsFatigue, mild nausea, hair loss and pink skin over the field
Blood countsNormal for five weeks; week 6 not drawn
Her questionWhether to use tumor-treating fields

Review of Systems

SystemResultFinding
ConstitutionalPositiveFatigue, worse each week; no fever; weight down 2.2 kg since the steroid stopped
GastrointestinalPositiveMild nausea after the doses, controlled; no vomiting; no constipation
IntegumentaryPositiveHair loss over the treated area; pink scalp without blisters
NeurologicalNegativeNo headache, seizure, speech change or new weakness
Hematologic and lymphaticNegativeNo bruising, nosebleeds or gum bleeding
RespiratoryNegativeNo cough or breathlessness
PsychiatricPositiveLow in energy and sometimes discouraged; PHQ-9 8, mostly from tiredness and sleep; no thoughts of self-harm

7 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for headache, no more than 3 g a dayTwo tablets every 6 hours as neededOral route2026-06-29activeS
Dexamethasone 4 mg oral tablet, one tablet twice a day with food, for symptomatic vasogenic edema, until surgeryOne tablet twice a day with breakfast and lunchOral route2026-06-30 to 2026-07-08completedS
Famotidine 20 mg oral tablet, one tablet twice a day while taking dexamethasoneOne tablet twice a dayOral route2026-06-30 to 2026-08-12completedS
Dexamethasone 2 mg oral tablet, one tablet twice a day after surgery, taperingOne tablet twice a dayOral route2026-07-10 to 2026-07-29completedS
Dexamethasone 2 mg oral tablet: one tablet daily for one week, then half a tablet daily for one week, then stopOne tablet daily for a week, then half a tablet daily for a weekOral route2026-07-29 to 2026-08-12completedS
Temozolomide 140 mg oral capsule, 140 mg (75 mg/m2) by mouth daily at bedtime on an empty stomach, seven days a week for 42 days from the first day of radiotherapyOnce daily at bedtime, seven days a week, for 42 daysOral route2026-08-03 to 2026-09-13completedS
Sulfamethoxazole 800 mg and trimethoprim 160 mg oral tablet, one tablet three times a week (Monday, Wednesday and Friday) to prevent Pneumocystis pneumoniaOne tablet on Monday, Wednesday and FridayOral route2026-08-03activeS
Ondansetron 8 mg oral tablet, one tablet 30 to 60 minutes before each temozolomide dose, and every 8 hours as needed for nauseaBefore each temozolomide dose; every 8 hours as neededOral route2026-08-03activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-09-14Body height180cmS
2026-09-14Body weight67.2kgS
2026-09-14Body mass index (BMI) [Ratio]20.7kg/m2S
2026-09-14Systolic blood pressure118mm[Hg]S
2026-09-14Diastolic blood pressure74mm[Hg]S
2026-09-14Heart rate80/minS
2026-09-14Respiratory rate16/minS
2026-09-14Body temperature36.8CelS
2026-09-14Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-09-14Hemoglobin [Mass/volume] in Blood11.9g/dL12-15.5 g/dLLowS
2026-09-14Leukocytes [#/volume] in Blood by Automated count3.610*3/uL4-11 10*3/uLLowS
2026-09-14Neutrophils [#/volume] in Blood by Automated count2.410*3/uL1.5-7.7 10*3/uLNormalS
2026-09-14Lymphocytes [#/volume] in Blood by Automated count0.510*3/uL1-4 10*3/uLLowS
2026-09-14Platelets [#/volume] in Blood by Automated count11210*3/uL150-400 10*3/uLLowS
2026-09-14Creatinine [Mass/volume] in Serum or Plasma0.8mg/dL0.59-1.04 mg/dLNormalS
2026-09-14Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M88mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-09-14Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma48U/L7-35 U/LHighS
2026-09-14Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma39U/L8-35 U/LHighS
2026-09-14Bilirubin.total [Mass/volume] in Serum or Plasma0.6mg/dL0.1-1.2 mg/dLNormalS
2026-09-14Glucose [Mass/volume] in Serum or Plasma96mg/dL70-99 mg/dLNormalS
2026-09-14Karnofsky Performance Status score80{score}S
2026-09-14Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]8{score}S

Physical Exam

Vital signs recorded on 2026-09-14; see the Vital Signs section. [S]

SystemFinding
GeneralTired but well; weight 67.2 kg; blood pressure 118/74, pulse 80, temperature 36.8 °C
HeadAlopecia over the left frontal field; grade 1 radiation dermatitis; incision healed
MouthNo ulcers or thrush
SkinNo bruising or petechiae
NeurologicalSpeech fluent; strength full in all four limbs; finger tapping equal; gait steady
ExtremitiesNo leg swelling or calf tenderness
PsychiatricTired, warm and engaged

Problems

ProblemClinical statusVerificationCodeProvenance
Three weeks of headaches on waking, with ten days of pauses in finding words and clumsiness of the right hand, in a previously well woman of 54: an intracranial lesion must be excluded. MRI of the brain with and without contrast booked for tomorrow morning, and neuro-oncology review bookedresolvedconfirmed R29.818S — Synthetic presenting problem; no symptom of her real illness was made public. Superseded when the MRI showed a brain mass.
Left posterior frontal ring-enhancing mass, 3.8 cm, with central necrosis, surrounding edema and 5 mm midline shift, next to the language and motor areas; presumed high-grade glioma, with no primary cancer elsewhere on CT; tissue diagnosis pendingresolvedconfirmed D49.6S — Synthetic imaging diagnosis before surgery; superseded by the pathology.
Glioblastoma, IDH-wildtype, CNS WHO grade 4, left posterior frontal lobe, MGMT promoter methylated, after gross total resection of the enhancing tumor; synthetic modern detail linked to her publicly reported brain canceractiveconfirmed C71.1S — Synthetic histology, molecular result and location; brain cancer is documented as the cause of her death (D), and nothing more about it was made public.
Late effects of childhood poliomyelitis: paralysis of the left leg in early childhood, treated with a metal brace, a special shoe, massage and heat, with full recovery of walking by about age 12 and a later career as an Olympic sprinter; no new weakness, fatigue or pain now to suggest post-polio syndromeactiveconfirmed B91S — Documented childhood polio (D); the current absence of new symptoms is synthetic.
Vasogenic cerebral edema around the left frontal mass, with 5 mm midline shift, causing headache and contributing to the language and right-hand symptoms; treated with dexamethasoneactiveconfirmed G93.6S — Synthetic finding on the first MRI.
Steroid-induced hyperglycemia on dexamethasone: random glucose 168 mg/dL, with an A1c of 5.6% before steroidsresolvedconfirmed R73.9S — Synthetic common effect of dexamethasone; resolved after the taper.
Lymphopenia from temozolomide, grade 2 (absolute lymphocytes 0.5 x 10^3/uL at the end of chemoradiation): Pneumocystis prophylaxis continues until recovery to grade 1 or betteractiveconfirmed D72.810S — Synthetic common effect of daily temozolomide with radiotherapy.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryBlood count with neutrophils, lymphocytes and plateletsWeekly during concurrent temozolomideCompleted todayHemoglobin 11.9 g/dL, white cells 3.6, neutrophils 2.4, lymphocytes 0.5, platelets 112: grade 1 thrombocytopenia and grade 2 lymphopenia
LaboratoryBlood count in week 6 of concurrent treatmentWeekly during concurrent temozolomideDeferredA deviation: not drawn in the last week of radiotherapy because the clinic's standing order was set for the Monday, a holiday that week, and was not moved. No harm resulted: today's count, a week later, shows platelets 112 and neutrophils 2.4, above the levels that would have stopped temozolomide, and she had no bleeding or fever. Corrective action: today's count; future standing orders are tied to treatment days, not a weekday
LaboratoryLiver tests (ALT, AST, bilirubin)Baseline, during treatment, before each cycle, and two to four weeks after the last doseCompleted todayALT 48, AST 39 U/L (grade 1), bilirubin 0.6 mg/dL; recheck before cycle 1
LaboratoryKidney function and glucoseEach visit; glucose after a steroid courseCompleted todayCreatinine 0.80 mg/dL, eGFR 88; glucose 96 mg/dL off dexamethasone
LaboratoryHepatitis B, hepatitis C and HIV screeningBefore chemotherapyUp to dateAll negative
Medication safetyPneumocystis pneumonia prophylaxisDuring concurrent temozolomide, and until lymphopenia is grade 1 or betterCompleted todayTaken as prescribed without rash; continues for grade 2 lymphopenia
Medication safetyAntiemetic before temozolomideEach doseCompleted todayOndansetron effective; no vomiting
ImagingMRI of the brain after chemoradiationAbout four weeks after radiotherapy, as the new baselineOrderedIn about three weeks; enhancement in the first three months may be treatment effect (pseudoprogression) and is read by RANO 2.0
ExaminationNeurologic examination (language, strength, gait)Each visitCompleted todayNo deficit; speech fluent; strength full
ExaminationRadiation skin reaction and hair lossWeekly during radiotherapy and at the endCompleted todayGrade 1 dermatitis; alopecia over the field
Medication safetySeizure history and antiseizure drug needEach visitNot indicatedNo seizure; no antiseizure drug
ExaminationSigns of leg clot or pulmonary embolismEach visitCompleted todayNone
SurveyPerformance status (Karnofsky)Each visitCompleted todayKarnofsky 80, from fatigue
Self-managementTumor-treating fieldsOffered with adjuvant temozolomide for supratentorial glioblastomaCompleted todayBenefits, daily wear and skin effects discussed; she chose to start them with cycle 1
ReferralPalliative careEarly, alongside cancer treatment, for a serious illness with a high symptom burdenReferredOutpatient consultation booked in two weeks
Self-managementFalls, leg strength and late effects of polioEach visitCompleted todayNo falls; home exercises at a gentler level; cane on uneven ground
SurveyDistress and depression screen (PHQ-9)At diagnosis, each treatment phase, and when symptoms changeCompleted todayPHQ-9 8, mostly from fatigue and sleep; no thoughts of self-harm

Goal progress:

Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Central Nervous System Cancers (2026); Weller M, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 2021;18(3):170-186 (PMID 33293629) (2021); Stupp R, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352(10):987-996 (PMID 15758009) (2005); Stupp R, et al. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma (EF-14). JAMA 2017;318(23):2306-2316 (PMID 29260225) (2017); Wen PY, et al. RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults. J Clin Oncol 2023 (PMID 37774317) (2023); TEMODAR (temozolomide) capsules, prescribing information (2026); Walbert T, et al. SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Neuro Oncol 2021;23(11):1835-1844 (PMID 34174071) (2021); Key NS, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2023;41(16):3063-3071 (PMID 37075273) (2023); Sanders JJ, et al. Palliative Care for Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2024;42(19):2336-2357 (PMID 38748941) (2024); Farbu E, et al. EFNS guideline on diagnosis and management of post-polio syndrome. Eur J Neurol 2006;13(8):795-801 (PMID 16879288) (2006); CMID: Clinical Monitoring Intelligence Database, depression monograph (2026); Depression and Suicide Risk in Adults: Screening (2023)

Follow-up: MRI in about three weeks; palliative care in two weeks. Review with the MRI result on the day adjuvant temozolomide starts. Call for fever, bruising, bleeding, a seizure, headache or new weakness. Next scheduled visit 2026-10-09: post-chemoradiation MRI result, day 1 of adjuvant temozolomide, the start of tumor-treating fields, and the palliative care plan. [S]